Efficacy of GLP-1 Receptor Agonist-Based Therapies on Cardiovascular Events and Cardiometabolic Parameters in Obese Individuals Without Diabetes: A Meta-Analysis of Randomized Controlled Trials.
semaglutidetirzepatideretatrutide
Journal of diabetesApr 2025
Efficacy and Safety of Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss Among Adults Without Diabetes : A Systematic Review of Randomized Controlled Trials.
semaglutidetirzepatideliraglutideretatrutide
Annals of internal medicineFeb 2025
Potential application of mono-, dual-, and triple-target GLP-1 receptor agonists in improving the prognosis of patients with diabetic foot ulcers.
Frontiers in endocrinologyJan 2025
Comparative efficacy of incretin drugs on glycemic control, body weight, and blood pressure in adults with overweight or obesity and with/without type 2 diabetes: a systematic review and network meta-analysis.
tirzepatideretatrutide
Frontiers in endocrinologyJan 2025
Survodutide for treatment of obesity: rationale and design of two randomized phase 3 clinical trials (SYNCHRONIZE™-1 and -2).
survodutide
Obesity (Silver Spring, Md.)Jan 2025
The efficacy and safety of danuglipron and orforglipron in patients with type 2 diabetes and obesity: a systematic review and meta-analysis.
orforglipron
Frontiers in endocrinologyJan 2025
Inflammatory biomarker response to GLP-1 receptor agonists versus other glucose-lowering medications in patients with type 2 diabetes: a systematic review and meta-analysis.
Frontiers in endocrinologyJan 2025
Efficacy and safety of triple hormone receptor agonist retatrutide for the management of obesity: a systematic review and meta-analysis.
retatrutide
Expert review of clinical pharmacologyJan 2025
Triple Agonism Based Therapies for Obesity.
tirzepatideretatrutide
Current cardiovascular risk reportsJan 2025
Survodutide for the Treatment of Obesity: Rationale and Design of the SYNCHRONIZE Cardiovascular Outcomes Trial.
survodutide
JACC. Heart failureDec 2024
Seven glucagon-like peptide-1 receptor agonists and polyagonists for weight loss in patients with obesity or overweight: an updated systematic review and network meta-analysis of randomized controlled trials.
A review of an investigational drug retatrutide, a novel triple agonist agent for the treatment of obesity.
retatrutide
European journal of clinical pharmacologyMay 2024
An overview of therapeutic options of obesity management in India: the Integrated Diabetes and Endocrinology Academy (IDEA) 2023 Congress update.
Expert review of clinical pharmacologyApr 2024
Phase 2
Dose-response effects on HbA and bodyweight reduction of survodutide, a dual glucagon/GLP-1 receptor agonist, compared with placebo and open-label semaglutide in people with type 2 diabetes: a randomised clinical trial.
semaglutidesurvodutide
DiabetologiaMar 2024
Phase 2
Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial.
survodutide
The lancet. Diabetes & endocrinologyMar 2024
Review article: Pharmacologic management of obesity - updates on approved medications, indications and risks.